ArmaGen, Inc., a secretly hold biotechnology association focused on building novel therapies to provide serious neurological disorders, announced currently that a Investigational New Drug (IND) focus for a company’s lead product candidate, AGT-182 for a diagnosis of Hunter syndrome, has been s…
FDA clears ArmaGen’s AGT-182 IND application for treatment of Hunter syndrome
Thursday, December 11, 2014
FDA clears ArmaGen’s AGT-182 IND application for treatment of Hunter syndrome
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment